Sofinnova Partners

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Gradient Denervation Technologies is a medical device company based in Paris, France, founded in 2019. It specializes in the development of an endovascular catheter-based technology designed to treat pulmonary hypertension. The device focuses on performing pulmonary artery denervation, which aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics. This innovative approach offers a minimally invasive solution for managing pulmonary hypertension and is built upon prior research and intellectual property developed at Stanford University. The company aims to provide the healthcare sector with a device that delivers consistent and long-lasting results for patients suffering from this condition.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative implantable medical devices aimed at restoring vision for individuals blinded by the degeneration of photoreceptor cells in the retina. The company’s flagship product, the PRIMA System, is a bionic vision system designed to improve visual acuity and enhance the independence of patients. Pixium Vision also works on the Intelligent Retinal Implantable System (IRIS1), which is currently undergoing clinical trials, and is developing two subsequent generations, IRIS2 and IRIS3, each designed to provide improved visual capabilities through advanced technologies. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with prestigious institutions such as Stanford University and Moorfields Eye Hospital to further its research and development efforts in retinal implant systems.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative implantable medical devices aimed at restoring vision for individuals blinded by the degeneration of photoreceptor cells in the retina. The company’s flagship product, the PRIMA System, is a bionic vision system designed to improve visual acuity and enhance the independence of patients. Pixium Vision also works on the Intelligent Retinal Implantable System (IRIS1), which is currently undergoing clinical trials, and is developing two subsequent generations, IRIS2 and IRIS3, each designed to provide improved visual capabilities through advanced technologies. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with prestigious institutions such as Stanford University and Moorfields Eye Hospital to further its research and development efforts in retinal implant systems.

Sensitive Object SA is a company specializing in the development of electronic products and touch-interface technology. Founded in 2003 and headquartered in Boulogne Billancourt, France, with additional operations in Paris and Singapore, the company focuses on a diverse range of applications including touch screens, consumer electronics, computing, outdoor interactive solutions, access control, home automation, healthcare, industrial control, and interactive digital advertising. Its product offerings encompass touch screens, peripherals, and control panels designed to enhance user interaction across various industries.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in embedded deep packet inspection (DPI) technologies for internet protocol traffic classification and network intelligence. The company offers a range of solutions, including ixEngine, a comprehensive software development kit that provides tools for decoding, protocol plugins, and real-time traffic flow classification. Its technology is applicable in various domains such as lawful interception, network protection, regulatory compliance, and content-based billing. Qosmos also develops solutions for virtual network functions and provides application classification and metadata extraction tailored for telecommunications and enterprise developers. With a focus on transforming networks into intelligent information sources, Qosmos enables users to analyze data traffic while supporting applications ranging from security to performance optimization. The company maintains additional offices in London, Silicon Valley, Tokyo, and Singapore and operates as a subsidiary of Enea AB.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in embedded deep packet inspection (DPI) technologies for internet protocol traffic classification and network intelligence. The company offers a range of solutions, including ixEngine, a comprehensive software development kit that provides tools for decoding, protocol plugins, and real-time traffic flow classification. Its technology is applicable in various domains such as lawful interception, network protection, regulatory compliance, and content-based billing. Qosmos also develops solutions for virtual network functions and provides application classification and metadata extraction tailored for telecommunications and enterprise developers. With a focus on transforming networks into intelligent information sources, Qosmos enables users to analyze data traffic while supporting applications ranging from security to performance optimization. The company maintains additional offices in London, Silicon Valley, Tokyo, and Singapore and operates as a subsidiary of Enea AB.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software, primarily catering to Fortune 500 companies. With additional offices in the UK and the US, the company employs over 80 staff members worldwide. Sefas' flagship product, the Open Print software suite, is utilized by various sectors, including financial services, banking, insurance, utilities, telecommunications, and the public sector, for designing, composing, and producing complex business-to-consumer documents. Its unique capability to integrate data from multiple sources allows for the creation of personalized communications. Recently, Open Print has been increasingly adopted for redesigning mission-critical documents to incorporate marketing campaigns, thereby generating new revenue opportunities. The UK office, established in 1999 in Bristol, serves notable clients such as Nationwide and British Telecom, who have been utilizing Sefas' solutions since the early 2000s.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Sensitive Object SA is a company specializing in the development of electronic products and touch-interface technology. Founded in 2003 and headquartered in Boulogne Billancourt, France, with additional operations in Paris and Singapore, the company focuses on a diverse range of applications including touch screens, consumer electronics, computing, outdoor interactive solutions, access control, home automation, healthcare, industrial control, and interactive digital advertising. Its product offerings encompass touch screens, peripherals, and control panels designed to enhance user interaction across various industries.